​

Apellis Pharmaceuticals (APLS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

APLS Stock Forecast

Apellis Pharmaceuticals (APLS) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $70.80, with a high of $92.00 and a low of $39.00. This represents a 140.24% increase from the last price of $29.47.

$25 $39 $53 $67 $81 $95 High: $92 Avg: $70.8 Low: $39 Last Closed Price: $29.47

APLS Stock Rating

Apellis Pharmaceuticals stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 1 Strong Buy (5.88%), 12 Buy (70.59%), 4 Hold (23.53%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 4 12 1 Strong Sell Sell Hold Buy Strong Buy

APLS Forecast vs Benchmarks

TypeNameUpside
StockApellis Pharmaceuticals140.24%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-112
Avg Price Target-$57.00$69.83
Last Closing Price$29.47$29.47$29.47
Upside/Downside-93.42%136.95%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 253118--22
Dec, 244118--23
Nov, 244117--22
Oct, 247116--24
Sep, 247104--21
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Douglas TsaoH.C. Wainwright$57.00$27.01111.03%93.42%
Sep 23, 2024Colleen KusyRobert W. Baird$92.00$31.75189.76%212.18%
Sep 20, 2024Annabel SamimyStifel Nicolaus$84.00$31.68165.15%185.04%
Sep 20, 2024Graig SuvannavejhMizuho Securities$39.00$36.736.18%32.34%
Sep 16, 2024Graig SuvannavejhMizuho Securities$42.00$37.6211.64%42.52%
Aug 09, 2024Colleen KusyRobert W. Baird$96.00$37.66154.91%225.76%
Aug 08, 2024Akash TewariJefferies$82.00$37.66117.74%178.25%
Aug 02, 2024Douglas TsaoH.C. Wainwright$83.00$36.00130.56%181.64%
Jul 26, 2024Colleen KusyRobert W. Baird$86.00$38.88121.19%191.82%
Jul 01, 2024Graig SuvannavejhMizuho Securities$49.00$38.3627.74%66.27%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jan 07, 2025RBC CapitalSector PerformSector Performhold
Nov 05, 2024Bank of America SecuritiesBuyBuyhold
Oct 16, 2024Wells FargoSector PerformSector Performhold
Oct 16, 2024William BlairOutperforminitialise
Sep 22, 2024CitigroupBuyBuyhold
Sep 13, 2024WedbushBuyBuyhold
Aug 09, 2024WedbushNeutralNeutralhold
Aug 08, 2024Goldman SachsBuyBuyhold
Aug 02, 2024UBSUnderperformUnderperformhold
Aug 02, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-9 $-3 $3 $9 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.59$-8.84$-8.68$-4.45-----
Avg Forecast$-5.85$-8.70$-6.27$-4.48$-1.66$-0.90$0.63$1.08$2.37
High Forecast$-6.86$-10.21$-7.37$-5.06$-1.88$-1.45$-2.05$-0.10$1.99
Low Forecast$-5.30$-7.89$-5.68$-3.86$-1.56$0.07$10.66$2.81$2.93
Surprise %-21.54%1.61%38.44%-0.67%-----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$250.65M$66.56M$75.42M$366.28M-----
Avg Forecast$98.49M$15.01M$76.64M$390.75M$766.78M$857.55M$1.08B$1.21B$1.46B
High Forecast$91.44M$13.93M$71.17M$386.55M$755.57M$777.37M$1.08B$1.21B$1.28B
Low Forecast$111.59M$17.00M$87.04M$396.54M$782.30M$1.02B$1.08B$1.22B$1.72B
Surprise %154.49%343.56%-1.59%-6.26%-----

Net Income Forecast

$-1B $-500M $0 $500M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-344.87M$-746.35M$-652.17M$-528.63M-----
Avg Forecast$-693.80M$-488.72M$-578.22M$-528.63M$-204.51M$-134.94M$-11.88M$156.49M$281.76M
High Forecast$-813.79M$-586.47M$-693.87M$-634.35M$-223.62M$-171.76M$-242.72M$-12.24M$236.38M
Low Forecast$-629.25M$-390.98M$-462.58M$-422.90M$-185.39M$7.85M$1.26B$333.91M$348.22M
Surprise %-50.29%52.71%12.79%------

APLS Forecast FAQ

Is Apellis Pharmaceuticals stock a buy?

Apellis Pharmaceuticals stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 12 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Apellis Pharmaceuticals is a favorable investment for most analysts.

What is Apellis Pharmaceuticals's price target?

Apellis Pharmaceuticals's price target, set by 17 Wall Street analysts, averages $70.8 over the next 12 months. The price target range spans from $39 at the low end to $92 at the high end, suggesting a potential 140.24% change from the previous close price of $29.47.

How does Apellis Pharmaceuticals stock forecast compare to the average forecast of its sector, industry, and investment themes?

Apellis Pharmaceuticals stock forecast shows a 140.24% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Apellis Pharmaceuticals over the past three months?

  • January 2025: 13.64% Strong Buy, 50.00% Buy, 36.36% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 17.39% Strong Buy, 47.83% Buy, 34.78% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 18.18% Strong Buy, 50.00% Buy, 31.82% Hold, 0% Sell, 0% Strong Sell.

What is Apellis Pharmaceuticals’s EPS forecast?

Apellis Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December is -1.66 for 2024, a -62.70% decrease from the reported $-4.45 in 2023. The prediction for 2025 is $-0.9, $0.63 for 2026, $1.08 for 2027, and $2.37 for 2028.

What is Apellis Pharmaceuticals’s revenue forecast?

Apellis Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December is $766.78M for 2024, a 109.34% increase from the reported $366.28M in 2023. The forecast for 2025 is $857.55M, $1.08B for 2026, $1.21B for 2027, and $1.46B for 2028.

What is Apellis Pharmaceuticals’s net income forecast?

For its fiscal year ending in December, Apellis Pharmaceuticals's average annual net income forecast is $-205M for 2024, reflecting a -61.31% decrease from the reported $-529M in 2023. The projection for 2025 is $-135M, $-11.883M for 2026, $156.49M for 2027, and $281.76M for 2028.